The experimental treatment donanemab is now the second antibody drug to slow cognitive decline in people with early stage Alzheimer's disease, but questions remain about its real-world benefits and safety
The experimental treatment donanemab is now the second antibody drug to slow cognitive decline in people with early stage Alzheimer's disease, but questions remain about its real-world benefits and safety
Share this Article
Recommended